A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients-Reference-Cited by-同舟云学术

A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients

Published:2022-01-28 Issue:1 Volume:76 Page:70-77
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Fukuda Naoki^ORCID,Toda Kazuhisa,Udagawa Shohei,Ohmoto Akihiro,Oki Ryosuke,Suto Hirotaka,Wang Xiaofei,Hayashi Naomi,Urasaki Tetsuya,Sato Yasuyoshi,Nakano Kenji,Ono Makiko,Tomomatsu Junichi,Mitani Hiroki,Takahashi Shunji

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s12020-021-02963-z.pdf

Reference28 articles.

1. B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)

2. S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L.D. Locati, K. Newbold, M.G. Papotti, A. Berruti; ESMO Guidelines Committee, Electronic address: clinicalguidelines@esmo.org: Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 30, 1856–1883 (2019)

3. L. Fugazzola, R. Elisei, D. Fuhrer, B. Jarzab, S. Leboulleux, K. Newbold, J. Smit, 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur. Thyroid J. 8, 227–245 (2019)

4. NCCN Clinical Practice Guidelines in Oncology, Thyroid Carcinoma Version 2. 2021. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed 27 Sep 2021

5. M.S. Brose, C.M. Nutting, B. Jarzab, R. Elisei, S. Siena, L. Bastholt, C. de la Fouchardiere, F. Pacini, R. Paschke, Y.K. Shong, S.I. Sherman, J.W. Smit, J. Chung, C. Kappeler, C. Peña, I. Molnár, M.J. Schlumberger; DECISION investigators., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014)

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients;Endocrine;2023-03-11

2. Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective;Cancer Management and Research;2022-10